Cargando…
Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response
Staphylococcus aureus causes severe disease in humans for which no licensed vaccine exists. A novel S. aureus vaccine (SA4Ag) is in development, targeting the capsular polysaccharides (CPs) and two virulence-associated surface proteins. Vaccine-elicited antibody responses to CPs are efficacious agai...
Autores principales: | Dupont, Christopher D., Scully, Ingrid L., Zimnisky, Ross M., Monian, Brinda, Rossitto, Christina P., O'Connell, Ellen B., Jansen, Kathrin U., Anderson, Annaliesa S., Love, J. Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106056/ https://www.ncbi.nlm.nih.gov/pubmed/30135219 http://dx.doi.org/10.1128/mSphere.00217-18 |
Ejemplares similares
-
Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine
por: Scully, Ingrid L., et al.
Publicado: (2014) -
Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection
por: Anderson, Annaliesa S., et al.
Publicado: (2016) -
Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease
por: Scully, Ingrid L., et al.
Publicado: (2021) -
Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors
por: Anderson, Annaliesa S., et al.
Publicado: (2012) -
Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against S. aureus and Staphylococcus epidermidis
por: Anderson, Annaliesa S., et al.
Publicado: (2012)